Browsing Tag
SKYRIZI
4 posts
AbbVie wins FDA nod expanding RINVOQ label to Crohn’s disease in major IBD market milestone
Find out how AbbVie’s FDA approval for RINVOQ in Crohn’s disease is reshaping IBD therapy and boosting investor confidence in its post-Humira strategy.
AbbVie delays Rinvoq generics until 2037—what it means for revenue, risk, and investor confidence
AbbVie secures Rinvoq exclusivity until 2037 through a key settlement, boosting revenue forecasts and pushing back generics—here’s what it means for investors.
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges…
AbbVie’s SKYRIZI wins FDA approval for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie,…